Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth PPO Formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 EmblemHealth PPO Formulary (PPOF) — Prescription Drug Coverage & Utilization Management

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered prescription drugs, tier assignments, and utilization management rules (e.g., prior authorization, quantity limits, step therapy) for EmblemHealth PPO members and their providers. It governs coverage and pharmacy benefit operations for members whose ID cards indicate the PPOF formulary.

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth PPO Formulary (PPOF) — Prescription Drug Coverage & Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked 'PA' to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01Effective date
    PPOFFormulary
    Tier 1-3Drug tiers
    24/7Member services
    multipleEntries with flags

    Coverage and Requirements Overview

    General Coverage Criteria

    Covered when the member’s drug is listed on the formulary and all plan-specified utilization management requirements are satisfied.

    Formulary Coverage Basic Conditions: Drug appears on the PPOF formulary and dispensing follows any Requirements/Limits indicated in the formulary entry (for example: PA, QL, ST, LA, SP, ACA).

    See member's Certificate of Coverage for cost-share and plan applicability.

    Access conditions tied to requirement flags

    Coverage and access depend on the drug’s tier and on explicit requirement flags shown in the Requirements/Limits column.

    General access rules for flagged drugs: If an entry is labeled PA, prior authorization must be obtained before coverage; if labeled QL, coverage is limited to the stated quantity and time period; if labeled ST, step therapy requirements must be met; if labeled LA or SP, restricted distribution or specialty pharmacy/site-of-care processes apply.

    Applies to formulary entries where these flags are present.

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth PPO Formulary (PPOF) — Prescription Drug Coverage & Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked 'PA' to avoid coverage denial.
    SourceLink
    On This Page
    Coverage and Requirements OverviewDrug Listings and Coding / Formulary ItemsPrior Authorization, Documentation, and Provider ResponsibilitiesStep Therapy / Program RulesQuantity Limits by Product (Examples)Site-of-Care and Specialty Pharmacy NotesPolicy BackgroundAbbreviations and Flags

    Coverage determination based on listed requirements

    Coverage and access are determined per the drug-level Requirements/Limits shown next to each product.

    Coverage determination based on listed requirements/limits: Formulary entries include Drug Tier and Requirements/Limits codes (ACA, OTC, PA, QL, SP, LA). Coverage is contingent on meeting those requirements: ACA/OTC items are subject to applicable mandates; items with PA/LA/SP require prior authorization and may require specialty pharmacy dispensing or limited access programs; items with QL are payable only up to the stated quantity within the specified time frame.

    Specific clinical PA criteria, prior authorization forms, and appeals processes are managed per the plan’s administrative procedures and are not detailed in this extract.

    A drug appearing on the formulary list is not an automatic guarantee of payment. The formulary and this guide note that coverage is contingent on plan terms; prior authorization (PA), adherence to listed Requirements/Limits (e.g., PA, QL, ST, LA, SP), and member-specific benefit design must be satisfied before the plan will pay. Refer to the member's Certificate of Coverage or member portal for plan-specific cost-share and coverage rules.

    Within the provided document fragments there are no line-item entries explicitly labeled as excluded; many products instead carry program flags (e.g., ACA, PA, QL, LA, SP) that control access. Where exclusions apply they would be noted in plan documentation—this extract does not list explicit drug exclusions.

    The visible extracts do not mark specific individual agents as excluded. Entries show drug names, tier assignments and program flags (for example, antiviral/HIV agents and certain specialty products list PA, QL, LA, or SP), but no medicines in these chunks are identified as expressly not covered.

    No clinical exclusion criteria are provided in this partial listing. The extract focuses on tiering and utilization controls (quantity limits, prior authorization, limited access, specialty routing) rather than enumerating clinical contraindications or exclusion rules.

    This segment does not present explicit clinical exclusions. Instead, many specialty and high-cost therapies are annotated with access controls such as PA, QL, LA, and SP, which determine coverage pathways and may restrict access if program requirements are not met.

    No clinical exclusions are stated in the provided fragment. The listing predominantly indicates program flags and mandated coverage annotations (for example, ACA markers for vaccine coverage) rather than explicit medically excluded items.

    Within the excerpted pages there are no entries explicitly designated as 'not medically necessary.' The content instead details covered products, their drug tiers, and any associated utilization controls—coverage determinations follow the listed Requirements/Limits and member plan documents.

    This extract does not identify any medications as medically unnecessary. Coverage stance in these chunks is governed by tier assignments and program flags; if a product is not covered or is considered not medically necessary, that status would be shown in the full plan documentation.

    Drug Listings and Coding / Formulary Items

    Covered NDC / Drug List (Anti-infectives & Penicillins)NDCCovered
    AMOX-CHEW-125-250amoxicillin (trihydrate) chew tab 125 mg, 250 mg - Drug Tier = 3
    AMOX-CAP-250-500amoxicillin (trihydrate) cap 250 mg, 500 mg - Drug Tier = 1
    AMOX-SUSPamoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml - Drug Tier = 1
    AMOX-TAB-500-875amoxicillin (trihydrate) tab 500 mg, 875 mg - Drug Tier = 1
    AMOX-CLAV-SUSP-200-28.5amoxicillin & k clavulanate for susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml - Drug Tier = 1
    AUGMENTIN-ES-600-SUSPamoxicillin & k clavulanate for susp 600-42.9 mg/5ml (Augmentin ES-600) - Drug Tier = 1
    AMOX-CLAV-ER-1000-62.5amoxicillin & k clavulanate tab ER 12hr 1000-62.5 mg - Drug Tier = 1
    AMOX-CLAV-TAB-250-125amoxicillin & k clavulanate tab 250-125 mg - Drug Tier = 1
    AMOX-CLAV-TAB-500-125amoxicillin & k clavulanate tab 500-125 mg - Drug Tier = 1
    AMOX-CLAV-TAB-875-125amoxicillin & k clavulanate tab 875-125 mg - Drug Tier = 1
    1–10 of 18
    1/2
    Antiviral / HIV Agents (Sample)NDC
    MARAVIROC-ORAL-SOLNmaraviroc oral soln 20 mg/ml - Drug Tier = 3; Requirements/Limits = QL (1840 mls/30 days)
    SOFOSBUVIR-TABS-200-400SOVALDI - sofosbuvir tab 200 mg, 400 mg - Drug Tier = 2; Requirements/Limits = PA, QL (28 tablets/28 days), SP
    STRIBILD-TABSTRIBILD - elvitegravir-cobicistat-emtricitabine-tenofovir DF tab 150-150-200-300 mg - Drug Tier = 3; Requirements/Limits = QL (30 tablets/30 days)
    SUNLENCA-TAB-PACKSUNLENCA - lenacapavir sodium tab therapy packs (4x300 mg, 5x300 mg) and tab 300 mg - Drug Tier = 3; Requirements/Limits = LA, QL, SP
    Other Anti-infectives (flags)NDC
    ATOVAQUONE-SUSPatovaquone susp 750 mg/5ml (Mepron) - Drug Tier = 1
    CAYSTON-INHALCAYSTON - aztreonam lysine for inhalation soln 75 mg - Drug Tier = 3; Requirements/Limits = LA, SP
    Vaccines and Biologics (ACA flagged examples)NDC
    ABRYSVO-RSVABRYSVO - rsv pre-fusion f a&b vaccine recomb for IM soln 120 mcg/0.5ml - Drug Tier = 2; Requirements/Limits = ACA
    ACTHIB-HIBACTHIB - haemophilus b polysaccharide conjugate vaccine for inj - Drug Tier = 2; Requirements/Limits = ACA
    COMIRNATY-2025COMIRNATY 2025-26 - COVID-19 mRNA vaccine PFizer IM susp pref syr 30 mcg/0.3ml - Drug Tier = 2; Requirements/Limits = ACA
    GARDASIL9GARDASIL 9 - HPV 9-valent recomb vaccine - Drug Tier = 2; Requirements/Limits = ACA
    SHINGRIXSHINGRIX - zoster vaccine recombinant adjuvanted IM inj 50 mcg/0.5ml - Drug Tier = 2; Requirements/Limits = ACA
    PNEUMOVAX23PNEUMOVAX 23 - pneumococcal vaccine polyvalent soln pref syr 25 mcg/0.5ml - Drug Tier = 2; Requirements/Limits = ACA
    Listed drug products (no billing codes) - examplesNDC
    NUZYRA-OMADACYCLINE-150NUZYRA - omadacycline tosylate tab 150 mg (base equivalent) - Drug Tier = 3; Requirements/Limits = LA
    Cardiac Antiarrhythmics (examples)NDC
    NORPACE-100-150NORPACE - disopyramide phosphate cap 100 mg, 150 mg - Drug Tier = 3
    NORPACE-CR-100-150NORPACE CR - disopyramide phosphate cap ER 12hr 100 mg, 150 mg - Drug Tier = 3
    PROPAFENONE-ER-225-325-425propafenone HCl cap ER 12hr 225 mg, 325 mg, 425 mg - Drug Tier = 1
    QUINIDINE-GLUCONATE-324quinidine gluconate tab ER 324 mg - Drug Tier = 1
    Antihypertensives (selected)NDC
    LOTREL-AML-BENAZEPRILamlodipine besylate-benazepril HCl cap various strengths (Lotrel) - Drug Tier = 1
    EXFORGE-AML-VALSARTANamlodipine besylate-valsartan tab various strengths (Exforge) - Drug Tier = 1
    ARBLI-LOSARTAN-SOLNARBLI - losartan potassium oral susp 10 mg/ml - Drug Tier = 3; Requirements/Limits = PA, QL (330 mls/30 days)
    ENALAPRIL-ORAL-SOLNenalapril maleate oral soln 1 mg/ml (Epaned) - Drug Tier = 1; Requirements/Limits = PA, QL (1200 mls/30 days)
    AMLOD-OLMESARTAN-AZORamlodipine besylate-olmesartan medoxomil tab (Azor) - Drug Tier = 1
    Diuretics (examples with special handling/limits)NDC
    DIURIL-CHLOROTHIAZIDE-SUSPDIURIL - chlorothiazide susp 250 mg/5ml - Drug Tier = 3; Requirements/Limits = PA, QL (1200 mls/30 days)
    FUROSEMIDE-ORAL-SOLN-10MGMLFUROSEMIDE - furosemide oral soln 10 mg/ml - Drug Tier = 1; Requirements/Limits = FF, PA, QL (1800 mls/30 days)
    FUROSEMIDE-TABSfurosemide tab 20 mg, 40 mg, 80 mg (Lasix) - Drug Tier = 1
    Antihyperlipidemics (examples)NDC
    ATORVA-TABSatorvastatin calcium tab 10 mg, 20 mg, 40 mg, 80 mg (Lipitor) - Drug Tier = 1; Requirements/Limits = ACA
    CHOLESTYRAMINE-POWDERcholestyramine powder 4 gm/dose (Questran) - Drug Tier = 1
    VASCEPA-ICOSAPENTVASCEPA - icosapent ethyl cap 0.5 gm, 1 gm - Drug Tier = 1
    Pulmonary Vascular / Cardiac Specialty AgentsNDC
    UPTRAVI-SELEXIPAG-ALL-STRENGTHSUPTRAVI - selexipag tab 200 mcg through 1600 mcg (200,400,600,800,1000,1200,1400,1600 mcg) - Drug Tier = 2; Requirements/Limits = LA, PA, QL (60 tablets/30 days), SP
    ALYFTREK-VANZ-TEZ-DEUTIALYFTREK - vanzacaftor-tezacaftor-deutivacaftor tab 4-20-50 mg and 10-50-125 mg - Drug Tier = 2; Requirements/Limits = LA, PA, QL
    KALYDECO-IVACAFTOR-TAB-150KALYDECO - ivacaftor tab 150 mg - Drug Tier = 2; Requirements/Limits = LA, PA, QL (60 tablets/30 days), SP
    KALYDECO-PACKET-5.8-75KALYDECO - ivacaftor packets 5.8 mg up to 75 mg - Drug Tier = 2; Requirements/Limits = LA, PA, QL (60 packets/30 days), SP
    Erectile Dysfunction (examples)NDC
    SILDENAFIL-TABSsildenafil citrate tab various strengths (Viagra/Revatio) - Drug Tier = 1; Requirements/Limits = QL
    TADALAFIL-TABStadalafil tab various strengths (Cialis/Adcirca) - Drug Tier = 1; Requirements/Limits = QL
    Selected Listed Products (partial)NDC
    TRIKAFTA-ELE-TEZ-IVACAFTOR-PACKSTRIKAFTA / elexacaftor-tezacaftor-ivacaftor packs and tablet configurations - Drug Tier = 2; Requirements/Limits = LA, PA, QL, SP
    ORKAMBI-LUMACAFTOR-IVACAFTORORKAMBI - lumacaftor-ivacaftor various tabs and granule packets - Drug Tier = 3; Requirements/Limits = LA, PA, QL, SP
    ALYFTREK-ADDITIONAL-CONFIGALYFTREK - additional pack/tablet configurations as listed - Drug Tier = 2; Requirements/Limits = LA, PA, QL, SP
    PEG3350-BOWEL-PREPSPEG 3350 formulations: Golytely/Moviprep and related (peg 3350-kcl-nacl-Na sulfate etc.) - Drug Tier = 1; Requirements/Limits = ACA
    Respiratory agents (selected)NDC
    PULMOZYMEPULMOZYME - dornase alfa inhal soln 2.5 mg/2.5ml - Drug Tier = 2; Requirements/Limits = SP
    SYMDEKO-TEZ-IVA-TAKSYMDEKO - tezacaftor-ivacaftor & ivacaftor pack configurations - Drug Tier = 2; Requirements/Limits = LA, PA, QL, SP
    TRIKAFTA-CONFIGSTRIKAFTA - elexacaftor-tezacaftor-ivacaftor configurations (multiple strengths/packet options) - Drug Tier = 2; Requirements/Limits = LA, PA, QL, SP
    Cystic Fibrosis & Pulmonary Fibrosis AgentsNDC
    ALYFTREK-VANZ-TEZ-DEUTI-2ALYFTREK - vanzacaftor-tezacaftor-deutivacaftor tab 4-20-50 mg; 10-50-125 mg - Drug Tier = 2; Requirements/Limits = LA, PA, QL (84/56 tablets/28 days)
    KALYDECO-IVACAFTOR-PACKETSKALYDECO - ivacaftor packets and tabs - Drug Tier = 2; Requirements/Limits = LA, PA, QL
    OFEV-NINTEDANIBOFEV - nintedanib esylate cap 100 mg, 150 mg - Drug Tier = 3; Requirements/Limits = LA, PA, QL (60 capsules/30 days)
    Gastrointestinal Agents (selected)NDC
    XIFAXAN-200-550XIFAXAN - rifaximin tab 200 mg (Drug Tier = 3) and 550 mg (Drug Tier = 2)
    PEG3350-MOVIPREPpeg 3350-kcl-nacl-na sulfate-na ascorbate-c for soln (Moviprep) and related Golytely formulations - Drug Tier = 1; Requirements/Limits = ACA
    POLYETHYLENE-GLYCOL-OTCpolyethylene glycol 3350 oral powder 17 gm/scoop - Drug Tier = 1; Requirements/Limits = ACA, OTC
    Formulary entries (no billing codes)NDC
    HOME-DELIVERY-NOTEHome delivery recommended for members refilling monthly for six months or longer
    QUANTITY-LIMIT-EXAMPLESQuantity limits examples: 30 tablets/30 days; 112 tablets/28 days; 8 kits/180 days

    Prior Authorization, Documentation, and Provider Responsibilities

    Prior Authorization

    Prior Authorization Requirement

    Prior Authorization (PA) is required for many listed products. When a drug is marked with PA the plan requires approval before the prescription is filled; failure to obtain prior authorization may result in the claim being denied or not covered. Providers should verify PA requirements prior to dispensing and follow the plan's prior authorization process.

    • PA = Prior Authorization required; obtain approval before dispensing or risk denial
    • Failure to obtain PA may result in noncoverage or claim denial
    Prior Authorization

    Prior authorization required for select agents

    Certain agents and product groups are explicitly designated as requiring prior authorization. Examples throughout the formulary include antifungals (CRESEMBA), hepatitis C agents (HARVONI, SOVALDI), specialty antivirals (GENVOYA with QL), and many oncology and high-cost drugs. Check the Requirements/Limits column for a PA flag on the specific product entry.

    • Examples of common PA-marked products: CRESEMBA, HARVONI, SOVALDI, GENVOYA
    • Check each formulary line item Requirements/Limits for the 'PA' flag
    Note

    Prior Authorization and coverage flags

    Products may carry one or more coverage flags that affect how they are managed: PA (Prior Authorization), QL (Quantity Limit), LA (Limited Availability), SP (Specialty), ACA (Affordable Care Act designation), ST (Step Therapy). These flags trigger specific administrative requirements — follow the indicated program/process for each flagged product.

    • PA, QL, LA, SP, ACA, ST are common flags seen in the Requirements/Limits column
    • Adhere to each flag's program requirements to avoid claim denials
    Prior Authorization

    Prior authorization required for select specialty drugs

    Many specialty and oncology oral agents require PA and often additional handling (LA or SP). Examples noted in the formulary include ENSACOVE, KOSELUGO, VITRAKVI, and others. Specialty drugs may also have quantity limits and limited distribution requirements.

    • Specialty agents frequently require PA + SP and may be limited to certain pharmacies
    • Examples: KOSELUGO (LA, PA, QL, SP), VITRAKVI (LA, PA, QL, SP)
    Prior Authorization

    Prior authorization required for select specialty agents

    Numerous specialty and high-cost endocrine/metabolic agents are subject to prior authorization (PA) and specialty pharmacy (SP) requirements (e.g., carglumic acid, cinacalcet, crinecerfont, GALAFOLD, Ravicti, IMCIVREE). Providers should prepare to submit supporting clinical documentation when requesting PA for these products.

    • Endocrine/metabolic specialty examples: CARBAGLU (PA, SP), CINACALCET (PA, SP), GALAFOLD (LA, PA, QL, SP)
    • Submit clinical justification and prior therapy history with PA requests
    Prior Authorization

    PA required for many PAH/specialty drugs

    Many pulmonary arterial hypertension (PAH) and specialty drugs require PA and often LA/SP designations (e.g., UPTRAVI, ADEMPAS, bosentan products, TYVASO). These products commonly include quantity limits and may have staged dosing or titration packs that are separately flagged — obtain authorization for both starter/titration packs and maintenance supplies where applicable.

    • PAH examples: UPTRAVI (LA, PA, QL, SP), TYVASO (PA, SP)
    • Titration/starter packs (e.g., UPTRAVI TITRATION PACK) may have separate PA/QL requirements
    Prior Authorization

    PA required for select antihyperlipidemics

    Some antihyperlipidemic agents (e.g., NEXLETOL, NEXLIZET) are subject to PA and quantity limits. Verify PA status and QL for newer or higher-tier lipid-lowering therapies before prescribing.

    • NEXLETOL, NEXLIZET = PA, QL (typically 30 tablets/30 days)
    • Check Requirements/Limits for coverage exceptions or ACA designations
    Prior Authorization

    Prior authorization required for listed specialty products

    Many listed specialty products are marked with combinations of LA, PA, SP and QL — examples include TRIKAFTA, KALYDECO, OFEV, ALYFTREK, CHOLBAM, and others. These flags indicate restricted distribution, specialty pharmacy handling, prior authorization, and quantity controls that must all be satisfied.

    • CF modulators and antifibrotics: TRIKAFTA, KALYDECO, OFEV = LA, PA, QL, SP
    • Liver and rare disease agents such as CHOLBAM = LA, SP
    Prior Authorization

    Prior authorization required for selected agents

    Several agents across the formulary are subject to PA along with other controls (LA, SP, QL). Examples include tasimelteon (PA, QL), orlistat/phentermine products (PA, QL), ZEPOSIA starter kits (PA, QL, SP), and many immunomodulators (OLYMPIANT-class entries). Confirm PA and plan-specific limits prior to dispensing.

    • Sleep, weight-loss, and MS starter kits often require PA and have QL limits
    • Starter kits and therapy packs (e.g., ZEPOSIA, MAVENCLAD, MAYZENT) commonly flagged LA/PA/QL/SP
    Denial Risk

    Authorization flags present

    Authorization flags (PA, LA, SP, QL) shown in the formulary are active triggers for coverage review. Claims for products marked with these flags may be denied without prior approval or if quantity limits are exceeded. Providers must follow PA procedures and document adherence to quantity limits.

    • Claims may be denied for missing PA or exceeding QL
    • LA/SP designations may restrict dispensing to specific pharmacies
    Denial Risk

    Authorization/denial triggers

    PA, LA, SP, and QL are common denial triggers when requests lack required information or when the requested quantity exceeds plan limits. Extended-release and high-strength formulations frequently have PA/QL rules (e.g., NUCYNTA ER, XTAMPZA ER). Ensure PA is submitted and QL is respected to reduce denial risk.

    • ER formulations often require PA and have QL — obtain authorization prior to dispensing
    • Provide full dosing and prior therapy history to minimize denials
    Denial Risk

    Prior authorization/quantity limit risk

    Not meeting PA or quantity limit (QL) requirements risks claim denial or nonpayment. Requests for products flagged PA/QL/LA/SP must include required documentation and be submitted per the plan's prior authorization process. Review the Requirements/Limits column for each drug to confirm applicable controls.

    • Noncompliance with PA/QL/LA/SP may result in claim denial
    • Verify plan-specific submission steps and required clinical information
    Note

    PA/LA/SP requirements

    When a product is labeled LA, PA, SP or QL, there are program requirements to meet. Limited Availability (LA) may restrict the number of dispensing sites; Specialty (SP) often requires use of a designated specialty pharmacy; Quantity Limits (QL) cap the reimbursable amount; PA requires clinical justification and approval.

    • LA: limited dispensing locations
    • SP: specialty pharmacy distribution and monitoring
    • QL: precise day/quantity limits listed per product
    Billing Rule

    Quantity and program flag triggers

    Quantity limits and other program flags shown in the Requirements/Limits column (e.g., QL 30 tablets/30 days, QL 28 packets/28 days) are enforced at claim adjudication. Prescribers should prescribe within these limits or provide justification when requesting exceptions via PA.

    • Adhere to QL values as listed (examples: GENVOYA QL 30/30, HARVONI QL 28/28)
    • Request QL overrides only with supporting clinical documentation
    Prior Authorization

    Prior authorization required for listed PA/LA drugs

    Products marked PA, LA, or SP in the Requirements/Limits column require prior authorization and may have limited distribution or specialty pharmacy requirements. Examples include many cystic fibrosis, rare disease, and oncology therapies. Confirm whether dispensing must occur through a specialty vendor and include that information in the PA request.

    • PA/LA drugs often restricted to specialty pharmacy dispensing
    • Check product line-item notes for pharmacy/channel restrictions
    Denial Risk

    PA/QL noncompliance

    Noncompliance with PA, LA, SP or QL (for example, failing to obtain approval or exceeding a quantity limit) may result in claim denial or member financial liability. Always confirm coverage details in the Certificate of Coverage and the member's specific plan before dispensing.

    • PA/QL/LA/SP noncompliance can trigger denials and member cost-sharing
    • Review member's Certificate of Coverage for plan-specific rules
    Billing Rule

    ER formulation controls

    Extended-release (ER) formulations and certain high-risk analgesics often have special controls: PA and QL are commonly applied (e.g., NUCYNTA ER, other ER opioid products). If prescribing ER formulations, include prior authorization and rationale to support necessity over alternatives.

    • ER formulations commonly require PA and have QL (quantity/30 days)
    • Provide justification for ER use versus immediate-release alternatives
    Denial Risk

    PA/QL/LA/SP may trigger denial

    PA, LA, SP and QL flags across the formulary may lead to coverage denial if requirements are not met. Providers should proactively identify flagged products, obtain necessary approvals, and ensure dispensing occurs through authorized channels to avoid interruptions in therapy.

    • Multiple flags on a product increase the administrative steps required
    • Coordinate with the member and specialty pharmacy early for high-cost therapies
    Denial Risk

    Failure to meet product Requirements/Limits

    Failure to meet the listed Requirements/Limits (PA, LA, SP, QL, ST, ACA) for a product may result in the claim not being processed or being denied. Always consult the Requirements/Limits column on the formulary page for the product and confirm member eligibility and plan-specific exceptions.

    • Requirements/Limits column is the authoritative source for program flags
    • Confirm member plan coverage and any group-specific notations (e.g., '*' next to tier)
    Documentation Required

    Quantity-limit documentation

    Quantity-limit documentation must be available for products showing QL (e.g., GENVOYA QL 30 tablets/30 days, ISENTRESS QL 60 tablets/30 days). When requesting a QL override, submit the clinical rationale and specify the requested quantity and duration.

    • List QL value in the PA request and include clinical justification for higher quantities
    • Examples: QL (30 tablets/30 days), QL (28 packets/28 days), QL (60 capsules/30 days)
    Documentation Required

    Required documentation when flags present

    When flags such as PA, LA, SP or QL are present, include required supporting documentation with the prior authorization submission: diagnosis, prior therapy trials, dosing/titration schedule, pharmacy preference (if SP/LA), and expected duration of therapy.

    • Essential PA documents: diagnosis, previous treatments, clinical notes, labs/imaging where applicable
    • For LA/SP products, include preferred specialty pharmacy or acknowledgement of limited dispensing
    Documentation Required

    Documentation of applicable requirements

    Providers must document applicable requirements when submitting PA — include clinical rationale, prior treatment history, dosing/titration details, and any monitoring plans required for safe use. Specialty therapies often require additional documentation such as genetic testing results or REMS enrollment.

    • Include genetic test results, REMS enrollment, or specialty monitoring plans when relevant
    • Staged dosing/titration packs should be documented separately in the PA
    Documentation Required

    Documentation for restricted products

    Restricted products (LA, SP) and PA/QL-labeled products require detailed documentation to support coverage. For specialty agents, include product-specific materials (e.g., therapy pack details, titration schedule, prior authorization forms from specialty pharmacy) with the PA request.

    • Provide therapy pack/titration details for products like UPTRAVI, TRIKAFTA, ZEPOSIA starter kits
    • Attach specialty pharmacy plan-of-care or enrollment documentation when requested
    Documentation Required

    Supporting documentation for PA

    PA requests should include supporting documentation for PA and limit exceptions (e.g., reason for quantity above QL, clinical failure of preferred agents, contraindications). Timely and complete documentation reduces review time and denial likelihood.

    • Supporting documents: clinician notes, prior medications tried, laboratory results, imaging
    • Document why preferred or lower-cost alternatives are inappropriate or contraindicated
    Documentation Required

    Specialty/PA documentation

    Specialty products require specialty/PA documentation: prescriber's specialty credentialing, treatment plan, expected duration, infusion or administration site, and monitoring requirements. Many specialty products in the formulary (e.g., hemophilia factors, high-cost biologics) are PA and SP flagged.

    • Include prescriber specialty and treatment site information for SP products
    • Examples: coagulation factors, hemophilia products, biologic immunomodulators
    Step Therapy

    Step therapy applies to select agents

    Step therapy (ST) applies to select agents. Products marked with ST require trying specified first-line drugs before higher-tier treatments will be approved. Examples include KERENDIA and some behavioral health and neurologic agents. Follow the plan's step edits when submitting PA to document failed trials of required agents if applicable.

    • ST = Step Therapy; evidence of trial(s) of first-line agent(s) may be required
    • Examples: KERENDIA (ST), AUVELITY (ST), FANAPT titration packs (ST)
    Step Therapy

    Step therapy / Specialty program requirements

    Step therapy and specialty program indicators (ST, SP) are present for multiple drugs. When ST is indicated, PA submissions should include documentation of trials and failures of the required step agents or justification for bypassing step therapy (e.g., intolerance, contraindication).

    • Document prior medication trials and reasons for failure when requesting exceptions to ST
    • SP programs may include additional enrollment steps or monitoring
    Note

    Formulary Lookup & Coverage Documentation

    Use the formulary index and the Requirements/Limits column to identify program flags and required documentation. Refer to the member's Certificate of Coverage and the member portal for plan-specific details. Contact the plan using the number on the member ID card for questions about PA submission processes.

    • Formulary index locates drugs and shows Requirements/Limits flags
    • Contact payer via the member ID card phone number for plan-specific PA procedures

    Step Therapy / Program Rules

    ProductST Flag / NotesRequirements / Typical Sequence
    General step therapy policyST — definitionStep therapy may require trying specified drugs first; see Requirements/Limits column for drug-level sequences. Failure to follow may result in noncoverage.
    ProductST Flag / NotesRequirements / Typical Sequence
    ARIKAYCE (amikacin liposome inhalation)No explicit ST shown; LA, PA, QL, SP presentRequirements/Limits = LA, PA, QL (28 vials/28 days), SP — managed as a specialty inhaled product (specialty routing and PA/QL apply).
    ProductST Flag / NotesRequirements / Typical Sequence
    PALFORZIA (peanut allergen powder) — Initial/Level productsStaged levels (Initial dose, Level 0–11, Maintenance, Titration) imply program sequencingRequirements/Limits = LA, SP for each level; dosing organized by level (Initial dose, Level 0–11, Maintenance, Titration) — staged program must be followed per manufacturer/payer processes prior to maintenance coverage.
    ProductST Flag / NotesRequirements / Typical Sequence
    KERENDIA (finerenone) 10/20/40 mgMarked STRequirements/Limits = QL (30 tablets/30 days), ST — step therapy edit applies as indicated in the Requirements/Limits field.
    ProductST Flag / NotesRequirements / Typical Sequence
    AUVELITY (dextromethorphan-bupropion)ST noted for similar agents in classRequirements/Limits = QL (60 tablets/30 days), ST — product flagged 'ST' indicates step therapy applies; follow payer step protocol for prior agents before approval.
    ProductST Flag / NotesRequirements / Typical Sequence
    FETZIMA (levomilnacipran? — class reference) / FLUOXETINE DRMarked STRequirements/Limits = ST noted for these higher-tier antidepressant formulations; prior step(s) required per plan before covering the ST-marked product.
    ProductST Flag / NotesRequirements / Typical Sequence
    Gabapentin formulations (e.g., Gralise, HORIZANT entries)Marked ST for some formulationsRequirements/Limits = QL with ST (examples: Gralise entries: QL values listed) — step therapy applies where 'ST' is indicated; require prior trial of preferred gabapentin or other first-line agents per step protocol.
    ProductST Flag / NotesRequirements / Typical Sequence
    Selected specialty / immunomodulatory agents (e.g., OTEZLA, RINVOQ, others)LA, PA, SP flags present — step edits may apply via PA processRequirements/Limits = LA, PA, QL, SP for many specialty agents — these flags indicate utilization management steps (PA, specialty routing) and may include plan-defined step requirements prior to coverage.
    ProductST Flag / NotesRequirements / Typical Sequence
    Products marked SP or LA (general category)SP/LA may indicate step or specialty program requirementsRequirements/Limits = SP or LA (varies by product) — designation implies plan-defined step therapy or specialty program enrollment must be met prior to coverage; follow Requirements/Limits and PA process for enrollment/step compliance.
    ProductST Flag / NotesRequirements / Typical Sequence
    Formulary extract (general) — no specific sequences presentNo explicit ST sequences listed in these chunksObservation: step therapy sequences are not specified in this fragment; where ST appears it is noted per individual product Requirements/Limits.
    ProductST Flag / NotesRequirements / Typical Sequence
    Various listed agents (tiering, PA/QL/LA flags present)No explicit step edits detailed in these chunksObservation: tiering and program flags (PA, QL, LA, SP) are present but explicit step therapy edit sequences are not described here — refer to Requirements/Limits per product.
    ProductST Flag / NotesRequirements / Typical Sequence
    Specialty agents requiring PA/SP (examples: OTEZLA, OLUMIANT, XELJANZ listed elsewhere)LA, PA, SP flags present; prior step requirements may applyRequirements/Limits = LA, PA, QL, SP — these agents require prior authorization and specialty pharmacy routing; step therapy requirements, if any, are managed via the PA/process and noted per product listing.
    ProductST Flag / NotesRequirements / Typical Sequence
    Formulary fragment — general noteStep therapy not explicitly defined in this fragment; many agents flagged LA/PA/QL insteadWhere step therapy applies it is indicated by 'ST' on the product line; in this fragment products are primarily annotated with PA, QL, LA, or SP rather than detailed step sequences.

    Quantity Limits by Product (Examples)

    inv-134: BICKE? (example entries list QL)
    Common QL formatQuantity limits are expressed as maximum units per time period (e.g., 30 tablets/30 days)
    Examples appear across formularyMultiple entries include QL values for tablets, pens, vials, mLs, packets and kits
    DocumentationDispensing must adhere to the listed QL when submitting claims
    inv-135: PAXLOVID — QL
    PAXLOVID pack-based QLQuantity limits vary by pack: QL 11 tablets/30 days; QL 20 tablets/30 days; QL 30 tablets/30 days depending on pack size
    Formulary tierPAXLOVID listed as Drug Tier = 2 with QL restrictions
    Provider actionAdhere to QL when dispensing and document pack dispensed
    inv-136: PREVYMIS — QL
    PREVYMIS (tablets) QLQL 200 tablets/365 days
    PREVYMIS (pellet pack) QLQL 800 packets/365 days for pellet formulation
    Annual limitQuantity limits for PREVYMIS are specified on a per-year basis (365 days)
    inv-137: SELZENTRY - maraviroc oral soln 20 mg/ml — 1840 mls
    SELZENTRY oral solution QLQL 1840 mls/30 days for maraviroc oral solution 20 mg/ml
    Drug TierSELZENTRY listed with Drug Tier = 3
    Dispensing noteAdhere to high-volume QL when filling solution formulations
    inv-138: SOVALDI - sofosbuvir tab — 28 tablets
    SOVALDI tablets QLQL 28 tablets/28 days for sofosbuvir tablets
    SOVALDI pellet pack QLQL 28 packets/28 days for sofosbuvir pellet pack formulations
    Authorization/settingSOVALDI entries include PA and SP designations in the formulary
    inv-139: VIREAD - tenofovir disoproxil fumarate tab — 30 tablets
    VIREAD tablets QLQL 30 tablets/30 days for tenofovir disoproxil fumarate tablets
    VIREAD powder QLQL 240 grams/30 days for oral powder formulation
    Multiple formulationsDifferent formulations have distinct QL entries (tablets vs powder)
    inv-140: VIREAD - tenofovir disoproxil fumarate oral powder — 240 grams
    VIREAD oral powder QLQL 240 grams/30 days for tenofovir disoproxil fumarate oral powder (40 mg/gm)
    Formulation calloutPowder formulation QL listed in grams rather than tablet units
    Dispensing implicationEnsure grams-based QL are applied at dispensing and in claims
    inv-141: XOFLUZA - baloxavir marboxil tab therapy pack — 2 tablets
    XOFLUZA therapy pack QLQL 2 tablets per therapy pack (specified as 2 tablets)
    Timeframe notedXOFLUZA therapy pack QL applies per specified period (noted in listing as 2 tablets/120 days elsewhere)
    Single-course therapyPack-based therapy limits reflect single-course antiviral use
    inv-142: zidovudine cap 100 mg — 180 capsules
    Zidovudine capsules QLQL 180 capsules/30 days for zidovudine capsules 100 mg
    Retrovir entryZidovudine (Retrovir) capsule entry specifies the 180-capsule limit
    Dispensing practiceApply capsule-based QL when processing claims for Retrovir capsule formulation
    inv-143: zidovudine syrup 10 mg/ml — 1920 mls
    Zidovudine syrup QLQL 1920 mls/30 days for zidovudine syrup 10 mg/ml
    Liquid formulationSyrup QL specified in milliliters due to liquid dosing
    Claim handlingEnsure mL-based QL enforced at point of sale and in claim adjudication
    inv-144: ENSACOVE — 30 capsules/30 days (25 mg); 60 capsules/30 days (100 mg)
    ENSACOVE capsule QL30 capsules/30 days for 25 mg strength; 60 capsules/30 days for 100 mg strength
    Strength-specific limitsDifferent strengths have separate QL entries (25 mg vs 100 mg)
    PA/SP flagsENSACOVE entries include PA/LA/SP designations in formulary where applicable
    inv-145: KOSELUGO — QL (420 capsules/30 days for 5 mg); QL (240 capsules/30 days for 7.5 mg)
    KOSELUGO capsule QLQL 420 capsules/30 days for 5 mg; QL 240 capsules/30 days for 7.5 mg
    LA/PA/SPKOSELUGO entries include LA, PA and SP designations in the formulary
    High-count QLVery large capsule QLs reflect chronic specialty therapy dispensing
    inv-146: MYFEMBREE — QL (30 tablets/30 days)
    MYFEMBREE tablets QLQL 30 tablets/30 days
    Monthly limitStandard monthly tablet QL applied to contraceptive/combo agents
    Formulary listingMYFEMBREE appears with QL in the Requirements/Limits column
    inv-147: VITRAKVI — QL (300 mls/30 days) for oral solution
    VITRAKVI oral solution QLQL 300 mls/30 days for larotrectinib oral solution
    Specialty flagsVITRAKVI entries include LA, PA and SP designations in the formulary
    Volume-based QLOral solution quantities specified in mLs rather than unit counts
    inv-148: SEMGLEE pens — 33
    SEMGLEE pens QLQL 33 pens/30 days for SEMGLEE pen injectors
    SEMGLEE vials QLQL 10 vials/30 days for SEMGLEE vials
    Insulin QLInsulin products have separate QL entries by presentation (pens vs vials)
    inv-149: SEMGLEE vials — 10
    SEMGLEE vials QLQL 10 vials/30 days for SEMGLEE vials
    Alternate presentationVial presentation has a lower QL than pen presentation in the formulary
    Dispensing channelObserve QL when dispensing vials and document quantity on claim
    inv-150: TOUJEO MAX SOLOSTAR pens — 33
    TOUJEO MAX SOLOSTAR pens QLQL 33 pens/30 days for TOUJEO MAX SOLOSTAR
    High-capacity penSpecified pen QL aligns to higher-concentration insulin presentation
    Formulary enforcementApply QL for pen devices at dispensing and claims
    inv-151: TOUJEO SOLOSTAR pens — 66
    TOUJEO SOLOSTAR pens QLQL 66 pens/30 days for TOUJEO SOLOSTAR
    Presentation differenceDifferent pen models have distinct QLs (MAX vs standard SoloStar)
    Claims handlingEnsure correct pen QL used on adjudication
    inv-152: CRENESSITY capsules — 60
    CRENESSITY capsules QLQL 60 capsules/30 days
    CRENESSITY oral solution QLQL 120 mls/30 days for oral solution formulation
    Specialty designationEntries show LA/PA/SP where applicable for specialty endocrine agents
    inv-153: CRENESSITY oral solution — 120
    CRENESSITY oral solution QLQL 120 mls/30 days
    Liquid dosing QLOral solution quantities are specified in mLs for dispensing accuracy
    Program flagsSpecialty/LA/PA flags may accompany this QL in the formulary
    inv-154: GALAFOLD capsules — 14
    GALAFOLD capsule QLQL 14 capsules/28 days for migalastat
    28-day periodGALAFOLD limit expressed across a 28-day period rather than 30-day month
    Specialty controlsGALAFOLD listing includes LA/PA/SP designations where applicable
    inv-155: IMCIVREE vials — 10
    IMCIVREE vials QLQL 10 vials/30 days for setmelanotide (IMCIVREE)
    LA/PA/SP flagsIMCIVREE entries include LA, PA and SP in the formulary
    Specialty dispensingApply specialty pharmacy routing and QL enforcement for IMCIVREE
    inv-156: ISTURISA 1 mg tablets — 240
    ISTURISA 1 mg tablets QLQL 240 tablets/30 days for ISTURISA 1 mg tablets
    ISTURISA 5 mg tablets QLISTURISA 5 mg listed separately with QL 300 tablets/30 days (see related entry)
    Program flagsISTURISA entries include LA, PA, QL and SP designations
    inv-157: ISTURISA 5 mg tablets — 300
    ISTURISA 5 mg tablets QLQL 300 tablets/30 days for ISTURISA 5 mg tablets
    High monthly QLHigher QL corresponds to tablet strength differences
    Formulary flagsISTURISA includes LA, PA, QL and SP where applicable
    inv-158: JYNARQUE therapy packs/tablets — varies (e.g., 56 tablets/28 days; 60/30; 30/30)
    JYNARQUE therapy pack/tablet QLsVaries by formulation: examples include 56 tablets/28 days; 60 tablets/30 days; 30 tablets/30 days depending on pack
    LA/PA/SP designationsJYNARQUE listings include LA, PA, QL and SP flags in the formulary
    Pack-specific limitsTherapy packs and individual tablet entries have separate QLs in the listing
    inv-159: OPFOLDA capsules — 8
    OPFOLDA capsules QLQL 8 capsules/28 days for miglustat (OPFOLDA)
    LA/PA/SP flagsOPFOLDA entry includes LA, PA, QL and SP designations
    28-day periodLimit specified per 28-day period as listed
    inv-160: tolvaptan (Samsca) 15 mg — 30
    Tolvaptan 15 mg QLQL 30 tablets/365 days for tolvaptan (Samsca) 15 mg
    Annual QLTolvaptan QLs are expressed per 365-day year rather than monthly
    Specialty flagEntries note SP designation in addition to QL
    inv-161: tolvaptan (Samsca) 30 mg — 60
    Tolvaptan 30 mg QLQL 60 tablets/365 days for tolvaptan (Samsca) 30 mg
    Annual limit rationaleHigher strength has greater annual tablet allowance as listed
    Formulary flagsTolvaptan entries include QL and SP in the formulary listing
    inv-162: various (e.g., ENTRESTO, TYVASO, UPTRAVI, VYNDAMAX, PDE5 agents) — examples include 30 tablets/30 days, 112 tablets/28 days, 1 kit/180 days, 8 kits/180 days, 60 tablets/30 days, QL (6 tablets/30 days) for...
    Examples across classesQuantity-limit examples include 30 tablets/30 days, 112 cartridges/28 days, 1 kit/180 days, 8 kits/180 days, 60 tablets/30 days
    ED/PDE5 QLPDE5 agents frequently limited to QL 6 tablets/30 days for some strengths
    ApplicationThese illustrative QLs are applied across varied product types (tablets, cartridges, kits)
    inv-163: UPTRAVI (selexipag) tablets — 60
    UPTRAVI tablets QLQL 60 tablets/30 days for selexipag (UPTRAVI)
    PA/LA/SP flagsUPTRAVI listing includes LA, PA, QL and SP designations
    Titration pack handlingTitration pack has separate QL (1 package/180 days)
    inv-164: UPTRAVI TITRATION PACK — 1 package
    UPTRAVI Titration Pack QLQL 1 package/180 days for UPTRAVI Titration Pack
    Package-based limitTitration packs are limited on an extended (180-day) basis
    Specialty routingUPTRAVI entries include LA, PA and SP flags
    inv-165: OFEV (nintedanib) — 60 capsules
    OFEV capsule QLQL 60 capsules/30 days for nintedanib (OFEV)
    PA/LA/SPOFEV entry includes LA, PA and SP designations in the formulary
    Monthly capsule limitStandard monthly capsule QL applied to OFEV
    inv-166: TRIKAFTA (various configurations) — 56 packets/28 days or 90 tablets/30 days depending on formulation
    TRIKAFTA packet/tablet QLQL 56 packets/28 days or 90 tablets/30 days depending on TRIKAFTA formulation
    Formulation-dependent limitsPackets (granules) vs tablet formulations have different QLs in the listing
    Specialty flagsTRIKAFTA entries include LA, PA, QL and SP designations
    inv-167: ALYFTREK — 84 tablets/28 days or 56 tablets/28 days depending on strength
    ALYFTREK tablet QLQL 84 tablets/28 days or 56 tablets/28 days depending on strength for ALYFTREK
    Strength-dependent limitsDifferent strengths of ALYFTREK carry distinct 28-day QLs
    Specialty designationALYFTREK entries include LA, PA, QL and SP where applicable
    inv-168: esomeprazole magnesium susp packet (Nexium) — 60 packets
    Esomeprazole packet QLQL 60 packets for esomeprazole magnesium suspension (Nexium)
    Packet-based limitPacket formulations have packet-count QLs separate from capsules/tabs
    Formulary noteApply packet QL when dispensing suspension or packet formulations
    inv-169: AURYXIA / FERRIC CITRATE tab 1 gm — 360 tablets
    AURYXIA / FERRIC CITRATE QLQL 360 tablets/30 days for ferric citrate (AURYXIA)
    High monthly tablet QLLarge monthly tablet limits reflect chronic renal therapy usage
    Formulary enforcementEnsure high-count QL applied during dispensing and adjudication
    inv-170: FOSRENOL powder pack 750 mg — 180 packs
    FOSRENOL powder pack QLQL 180 packs/30 days for FOSRENOL 750 mg powder packs
    Pack-based limitsPowder packs have pack-count QLs distinct from tablet entries
    Chronic therapy implicationHigh pack limits reflect ongoing phosphate binder therapy
    inv-171: OMVOH mirikizumab-mrkz prefill syringe — 1 syringe
    OMVOH prefill syringe QLQL 1 syringe/28 days for mirikizumab-mrkz (OMVOH) prefilled syringe
    PA/SP flagOMVOH entry includes PA and SP designations in the formulary
    Monthly/28-day limitSyringe-based QL typically enforced per 28-day period as listed
    inv-172: oxybutynin solution 5 mg/5ml — 600 mls
    Oxybutynin solution QLQL 600 mls/30 days for oxybutynin solution 5 mg/5 ml
    Liquid dosage limitLiquid formulations have mL-based QLs for dispensing
    Apply QL at dispensingEnsure mL-based QL enforced on claim submission
    inv-173: estradiol vaginal cream — 255 grams
    Estradiol vaginal cream QLQL 255 grams per year (365 days) for estradiol vaginal cream
    Annual QL expressed in gramsSome topical products have annual quantity limits stated in grams
    Formulary noteApply gram-based limits as specified when adjudicating claims
    inv-174: bupropion hcl tab er 24hr 300 mg (Wellbutrin xl) — 30 tablets
    Wellbutrin XL QLQL 30 tablets/30 days for bupropion HCl ER 300 mg (Wellbutrin XL)
    Monthly tablet limitStandard monthly QL applies to extended-release antidepressant formulations
    Formulary enforcementApply 30-day QL at point of dispensing and in claim adjudication
    inv-175: desvenlafaxine succinate tab er 24hr 25 mg, 50 mg (Pristiq) — 30 tablets
    Pristiq QLQL 30 tablets/30 days for desvenlafaxine succinate ER (Pristiq)
    Standard monthly QLApplied to ER antidepressant formulations as listed
    Claims handlingFollow QL when processing ER antidepressant prescriptions
    inv-176: escitalopram oxalate soln 5 mg/5ml — 600 mls
    Escitalopram solution QLQL 600 mls/30 days for escitalopram oxalate oral solution 5 mg/5 ml
    Liquid antidepressant QLSolution formulations have mL-based QLs specified
    Dispensing enforcementEnsure mL QL enforced in pharmacy claims
    inv-177: fluoxetine hcl cap 10 mg — 240 capsules
    Fluoxetine capsule QLQL 240 capsules/30 days for fluoxetine HCl 10 mg capsules
    Monthly capsule limitHigh-count capsule QL listed for common SSRI formulations
    Formulary noteApply capsule QL when dispensing and adjudicating claims
    inv-178: clozapine orally disintegrating tab 25 mg — 270 tablets
    Clozapine ODT QLQL 270 tablets/30 days for clozapine orally disintegrating 25 mg
    Monthly tablet QLHigh monthly QL applied to clozapine ODT formulations
    Safety/program flagsClozapine entries include monitoring requirements beyond QL (refer to full policy)
    inv-179: quetiapine fumarate tab 25 mg, 50 mg, 100 mg, 200 mg (Seroquel) — 90 tablets
    Seroquel tablet QLQL 90 tablets/30 days for quetiapine fumarate immediate-release formulations (25–200 mg)
    Formulation groupingMultiple strengths listed under same QL in formulary extract
    Dispensing practiceApply the 30-day QL when dispensing Seroquel tablets
    inv-180: venlafaxine hcl tab 25 mg — 450 tablets
    Venlafaxine tablet QLQL 450 tablets/30 days for venlafaxine HCl 25 mg (high-count supply)
    Large outpatient supplyHigh-count QL may reflect allowances for daily multiple-dose regimens
    Claims enforcementEnsure QL enforcement for venlafaxine when adjudicating claims
    inv-181: dextroamphetamine sulfate oral solution 5 mg/5ml — 1800 mls
    Dextroamphetamine solution QLQL 1800 mls/30 days for dextroamphetamine sulfate oral solution 5 mg/5 ml
    Liquid stimulant QLSolution formulations list large mL QLs for chronic therapy
    Apply QL at dispensingEnforce mL-based limit during pharmacy claim processing
    inv-182: atomoxetine hcl cap 18 mg, 25 mg — 120 capsules
    Atomoxetine lower-dose QLQL 120 capsules/30 days for atomoxetine 18 mg and 25 mg capsules
    Atomoxetine higher-dose QLQL 30 capsules/30 days for atomoxetine 60 mg, 80 mg, 100 mg capsules
    Strength-differentiated QLDifferent strengths have distinct QLs as listed
    inv-183: atomoxetine hcl cap 60 mg, 80 mg, 100 mg — 30 capsules
    Atomoxetine high-dose QLQL 30 capsules/30 days for atomoxetine 60 mg, 80 mg, 100 mg formulations
    Short-term dispensingLower monthly QL for higher-strength capsules compared with lower strengths
    Claims noteEnsure correct strength-specific QL enforced
    inv-184: multiple stimulant formulations (dexmethylphenidate, dextroamphetamine, methylphenidate, lisdexamfetamine) — varies per formulation (examples: QL 30-360 units/30 days or larger where indicated)
    Stimulant formulations QL rangeQLs for stimulant products vary widely by formulation (examples: 30–360 units/30 days depending on product)
    Formulation-dependent limitsCapsules, tablets, and liquid forms have distinct QLs in the formulary
    Program flagsSome stimulant entries include PA, ST, or SP flags where applicable
    inv-185: ORLISTAT / XENICAL — QL (90 capsules)
    Orlistat / Xenical QLQL 90 capsules/30 days for orlistat (Xenical)
    PA flagOrlistat entries include PA in some formularies (listed here as PA, QL)
    Weight-management productsPhentermine and related products have QL entries that vary by formulation
    inv-186: phentermine products — QL (30 or 90 units depending on formulation)
    Phentermine QLsQL 30 or 90 units/30 days depending on formulation (tablet or capsule) as noted
    PA/QL flagsCertain phentermine products carry PA and QL designations
    Dispensing guidanceApply formulation-specific QL when dispensing and adjudicating claims
    inv-187: ZEPOSIA STARTER KIT - ozanimod cap pack — 28 capsules/180 days
    ZEPOSIA Starter Kit QLQL 28 capsules/180 days for ZEPOSIA starter kit (ozanimod)
    ZEPOSIA 7-day pack QLQL 7 capsules/180 days for ZEPOSIA 7-day starter pack
    PA and SPZEPOSIA starter kits require PA and are designated SP in the formulary
    inv-188: ZEPOSIA 7-DAY STARTER PAC - ozanimod cap pack — 7 capsules/180 days
    ZEPOSIA 7-day starter pack QLQL 7 capsules/180 days for the 7-day ozanimod starter pack
    Extended-period QLStarter packs are limited across a 180-day period in the formulary
    PA requirementStarter packs require prior authorization as indicated in the formulary
    inv-189: butalbital-acetaminophen tab — 180 tablets/30 days
    Butalbital-acetaminophen QLQL 180 tablets/30 days for butalbital-acetaminophen formulations
    High monthly capLarge 30-day QL reflects frequent use limits for analgesic combinations
    Apply at dispensingEnforce 180-tablet limit at point of sale and in claims adjudication
    inv-190: BELBUCA - buprenorphine buccal film — 60 films/30 days
    BELBUCA films QLQL 60 films/30 days for BELBUCA buprenorphine buccal film
    PA flagBELBUCA entries include PA and QL designations in the formulary
    Opioid partial agonist controlsApply QL and PA when dispensing buprenorphine buccal films
    inv-191: butorphanol tartrate nasal soln 10 mg/ml — 7.5 ml/30 days
    Butorphanol nasal solution QLQL 7.5 mls/30 days for butorphanol tartrate nasal solution 10 mg/ml
    Morphine solution QLQL 2700 mls/30 days for morphine sulfate oral solution 10 mg/5 ml
    Liquid opioid limitsLarge mL QLs exist for liquid opioid formulations and must be enforced
    inv-192: morphine sulfate oral soln 10 mg/5ml — 2700 mls/30 days
    Morphine oral solution QLQL 2700 mls/30 days for morphine sulfate oral solution 10 mg/5 ml
    High-volume liquid QLLiquid opioid solution allowances are expressed in mLs and can be large (e.g., 2700 mls)
    Claims enforcementEnsure mL-based QL enforced during dispensing and claim adjudication
    inv-193: NUCYNTA ER - tapentadol ER — 60 tablets/30 days
    NUCYNTA ER QLQL 60 tablets/30 days for NUCYNTA ER (tapentadol ER)
    PA/QL flagsNUCYNTA ER listing includes PA and QL designations in formulary
    ER formulation controlExtended-release analgesics commonly require PA and have QLs
    inv-194: XTAMPZA ER - oxycodone cap ER 12hr — 60 capsules/30 days (some strengths list 240 capsules/30 days)
    XTAMPZA ER QLQL 60 capsules/30 days for many strengths of XTAMPZA ER; some strengths list 240 capsules/30 days
    Strength-specific exceptionsCertain strengths of XTAMPZA ER have higher QLs (e.g., 240 capsules/30 days)
    PA requirementXTAMPZA ER entries include PA and QL designations in the formulary
    inv-195: OLIMIANT - baricitinib — 30 tablets/30 days
    OLIMIANT tablet QLQL 30 tablets/30 days for baricitinib (OLUMIANT)
    PA/SP flagsSome immunomodulatory agents include PA and SP designations alongside QL
    Monthly tablet limitStandard 30-day QL applied to OLIMIANT
    inv-196: XELJANZ - tofacitinib — varies by formulation (examples: 60 tablets/30 days; 240 mls/30 days for oral solution)
    XELJANZ QL examplesQuantity limits vary by formulation: examples include 60 tablets/30 days for tablets and 240 mls/30 days for oral solution
    PA/QL/SPXELJANZ entries include PA, QL and SP designations in the formulary
    Formulation-specific enforcementApply correct tablet vs solution QL during dispensing and claims processing
    inv-197: FINTEPLA — 360 mls/30 days
    FINTEPLA solution QLQL 360 mls/30 days for FINTEPLA oral solution
    LA/PA/SP flagsFINTEPLA listing includes LA, PA and SP designations
    Apply mL-based QLEnsure 360 mls/30 days limit enforced for solution formulations
    inv-198: pregabalin (various strengths) — range by strength (360, 270, 180, 90, 60 capsules/30 days)
    Pregabalin QL rangeQuantity limits vary by strength: examples include 360, 270, 180, 90, 60 capsules/30 days depending on strength
    Strength-specific limitsDifferent strengths of pregabalin have distinct monthly QLs
    Formulary enforcementApply strength-specific QL when dispensing pregabalin formulations
    inv-199: DAYBUE — 8 bottles/30 days
    DAYBUE bottle QLQL 8 bottles/30 days for DAYBUE oral solution
    DAYBUE STIX QLQL 120 or 60 packets/30 days for DAYBUE STIX depending on pack size
    PA/SP flagsDAYBUE entries include LA, PA, QL and SP designations in formulary
    inv-200: DAYBUE STIX — 120 or 60 packets/30 days depending on pack
    DAYBUE STIX packet QLQL 120 or 60 packets/30 days depending on pack for DAYBUE STIX
    Pack-size dependent limitsDifferent pack sizes have separate QLs as listed
    Specialty routingEntries include PA and SP flags where applicable
    inv-201: DUVYZAT — 3 bottles/30 days
    DUVYZAT bottle QLQL 3 bottles/30 days for DUVYZAT oral suspension
    PA/SP flagsDUVYZAT entries include PA, QL and SP designations in formulary
    Monthly limitApply 30-day QL for DUVYZAT dispensing
    inv-202: EVRYSDI (tablets) — 30 tablets/30 days
    EVRYSDI tablets QLQL 30 tablets/30 days for EVRYSDI (risdiplam) tablets
    EVRYSDI solution QLQL 240 mls/30 days for EVRYSDI oral solution
    LA/PA/SPEVRYSDI entries include LA, PA, QL and SP in the formulary
    inv-203: EVRYSDI (solution) — 240 mls/30 days
    EVRYSDI solution QLQL 240 mls/30 days for EVRYSDI oral solution
    Specialty designationEVRYSDI listings note LA, PA, QL and SP where applicable
    Dispensing enforcementApply mL-based QL for solution formulations on claims
    inv-204: RADICAVA ORS — 50 mls/28 days (starter kit 70 mls/180 days)
    RADICAVA ORS QLQL 50 mls/28 days for RADICAVA ORS oral suspension; starter kit QL 70 mls/180 days
    Starter kit exceptionStarter kit has extended 180-day QL separate from regular 28-day limit
    PA/SP flagsRADICAVA entries include LA, PA, QL and SP designations

    Site-of-Care and Specialty Pharmacy Notes

    Billing Rule

    Route SP/LA Products via Specialty Pharmacy / Follow Site Controls

    Products marked 'SP' are dispensed through specialty pharmacy channels and 'LA' denotes limited distribution or site constraints; providers should route dispensing through the specialty pharmacy and follow site‑of‑care rules when indicated.

    • SP = specialty pharmacy dispensing
    • LA = limited access / restricted distribution
    Billing Rule

    Use Specialty Pharmacy for SP‑Designated Products

    Specialty (SP) products frequently require dispensing via a specialty pharmacy and may involve limited‑access programs (LA); coordinate with the specialty pharmacy and include PA documentation and shipping instructions as required.

    Note

    Confirm Site‑of‑Care (Infusion Center / Home / Specialty Pharmacy) for LA/SP Agents

    Certain specialty infusions and therapies flagged SP or LA may need administration at an infusion center, home infusion program, or through specialty pharmacy channels; confirm site‑of‑care requirements and obtain PA if required.

    • Infusion‑administered agents may require LA or SP routing
    • Confirm infusion center authorization and billing expectations
    Note
    Note

    Policy Background

    This formulary lists drug classes and individual products together with assigned Drug Tiers (1–3) and any Requirements/Limits such as PA (prior authorization), QL (quantity limits), ST (step therapy), LA (limited access), and SP (specialty). Use the Requirements/Limits column to determine whether prior approval, quantity limits, specialty dispensing, or ACA-mandated coverage applies for a given product; final coverage and member cost-share are determined by the Certificate of Coverage and the member's plan.

    Abbreviations and Flags